Mayer and Arteaga suggested, in an accompanying editorial [46], that the apparent discrepant role of PIK3CA mutations in early versus late ER+ breast cancer might be explained by a predominant role of PIK3CA mutations in secondary endocrine resistance [46]. This evidence concerns the gene PIK3CA and breast carcinoma.